Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes

European Journal of Haematology

Volumn 80, Issue 3, 2008, Pages 216-226

  Travaglino, Erica ^a   Benatti, Chiara ^a   Malcovati, Luca ^a   Porta, Matteo Giovanni Della ^a   Gallì, Anna ^a   Bonetti, Elisa ^a   Rosti, Vittorio ^a   Cazzola, Mario ^a   Invernizzi, Rosangela ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Acute myeloid leukaemia; Immunocytochemistry; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Myelodysplastic syndrome

Indexed keywords

GELATINASE A; GELATINASE B;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CANCER SURVIVAL; CELL CULTURE; CELL FUNCTION; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ANALYSIS; ENZYME RELEASE; ERYTHROBLAST; FEMALE; HEMATOPOIETIC CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; APOPTOSIS; BONE MARROW; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROBLASTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; NEOPLASM INVASIVENESS; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 39149091719     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01012.x     Document Type: Article

References (40)

1. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990 87: 5578 82.
2. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999 274: 21491 4.
3. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000 1477: 267 83.
4. Giavazzi R, Taraboletti G. Preclinical development of metalloproteinases inhibitors in cancer therapy. Crit Rev Oncol Hematol 2001 37: 53 60.
5. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000 36: 1621 30.
6. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002 295: 2387 92.
7. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002 2: 161 74.
8. Herbst RS, Yano S, Kuniyasu H, et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000 6: 790 7.
9. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J, Dienes HP, Holscher AH. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001 39: 597 602.
10. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001 7: 2396 404.
11. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002 99: 157 66.
12. Rothenberg ML, Nelson AR, Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem cells 1999 17: 237 40.
13. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001 93: 178 93.
14. Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003 44: 213 22.
15. De Bont ESJM, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001 113: 296 304.
16. Kuittinen O, Savolainen ER, Koistinen P, Mottonen M, Turpeenniemi-Hujanen T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res 2001 25: 125 31.
17. Sawicki G, Matsuzaki A, Janowska-Wieczorek A. Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion. J Cancer Res Clin Oncol 1998 124: 245 52.
18. Janowska-Wieczorek A, Marquez LA, Matzuzaki A, Hashmi HR, Larratt LM, Boshkov LM, Turner AR, Zhang MC, Edwards DR, Kossakowska AE. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 1999 105: 402 11.
19. Ries C, Loher F, Zang C, Ismair MG, Petrides P. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndrome. Clin Cancer Res 1999 5: 1115 24.
20. Marquez-Curtis LA, Dobrowsky A, Montaño J, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol 2001 115: 595 604.
21. Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Gelatinase A and B (MMP-2, MMP-9) in leukemia. MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999 19: 4395 400.
22. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002 117: 835 41.
23. Klein G, Vellenga E, Fraaje MW, Kamps WA, de Bont ESJM. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukaemia. Crit Rev Oncol Hematol 2004 50: 87 100.
24. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001 97: 1427 34.
25. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997 89: 2079 88.
26. Negoescu A, Lorimier P, Labat-Moleur F, Drouet C, Robert C, Guillermet C, Brambilla C, Brambilla E. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 1996 44: 959 68.
27. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000 111: 43 51.
28. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002 118: 151 6.
29. Stetler-Stevenson M, Mansoor A, Lim M, Fukushima P, Kehrl J, Marti G, Paszynski K, Wang J, Stetler-Stevenson WG. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 1997 89: 1708 15.
30. Redondo-Muñoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by α4β1 integrin or CXCR4 engagement via distinct signalling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006 108: 3143 51.
31. Arimura K, Arima N, Matsushita K, et al. Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur J Haematol 2004 73: 17 24.
32. Iwata M, Pillai M, Ramakrishnan A, Hackman RC, Deeg HJ, Opdenakker G, Torok-Storb B. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 2007 109: 85 92.
33. Shibakura M, Niiya K, Kiguchi T, Shinagawa K, Ishimaru F, Ikeda K, Namba M, Nakata Y, Harada M, Tanimoto M. Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-trans retinoic acid in human PL-21 and NB4 myeloid leukaemia cells. Br J Haematol 2002 118: 419 25.
34. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, Li G. IL-18 increases invasiveness of HL-60 myeloid leukaemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res 2004 28: 91 5.
35. Liu J, Lu H, Huang R, et al. Peroxisome proliferators activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukaemia cells. Cancer Chemother Pharmacol 2005 56: 400 8.
36. Nakamura Y, Sato K, Wakimoto N, Kimura F, Okuyama A, Motoyoshi K. A new matrix metalloproteinase inhibitor SI-27 induces apoptosis in several human myeloid leukaemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis. Leukemia 2001 15: 1217 24.
37. Invernizzi R, Travaglino E, De Amici M, Brugnatelli S, Ramajoli I, Rovati B, Benatti C, Ascari E. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk Res 2005 29: 641 7.
38. Borregaard N, Sehested M, Nielsen BS, Sengelov H, Kjeldsen L. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 1995 85: 812 7.
39. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H, Rozmus J, Russel JA, Edwards DR, Turner AR. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood 1999 93: 3379 90.
40. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002 109: 625 37.